chrisvoncsefalvay/vaers-outcomes huggingface dataset:
2 days after receiving the HPV vaccine, patient had weakness, tingling in both legs and bilateral knee pain and had difficulty ambulating. She was taken to ER.
Morning after DTP shot, arm was red 1/2in below shot, swollen fire red; area that is red is about  1.5in in diameter;
This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (lot of pain her arm), ABDOMINAL PAIN (lot of pain in her belly) and ABDOMINAL PAIN UPPER (lot of pain in her stomach) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 06-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-May-2021, the patient experienced PAIN IN EXTREMITY (lot of pain her arm), ABDOMINAL PAIN (lot of pain in her belly) and ABDOMINAL PAIN UPPER (lot of pain in her stomach). At the time of the report, PAIN IN EXTREMITY (lot of pain her arm), ABDOMINAL PAIN (lot of pain in her belly) and ABDOMINAL PAIN UPPER (lot of pain in her stomach) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication and treatment information were not reported. The patient wanted to know what medication to take.
Felt dizzy. A few minutes after shot, she was conscious, flushing (shortness of breath) and lying down (jerking movement). 911 contacted, but no First responders requested due to recovery in a few minutes according to her. Water bottle was given.
Patient is a 84-year-old female presenting to the emergency room with anxiousness, generalized weakness and one episode of vomiting/nausea surrounding her Covid vaccination this afternoon.  On exam patient appears mildly anxious, has no evidence of allergic reaction, lungs are clear and equal bilaterally.  Patient is resting comfortably, speaking in complete sentences.  Shortly after physical exam patient was noted to have oxygen saturation of 90 to 92%, subsequently placed on 2 L nasal cannula.  Will obtain CBC, CMP, chest x-ray, EKG.  We will also give patient 500 cc of fluid and 4 mg of Zofran for control of nausea and vomiting.  We will continue to monitor patient. No leukocytosis, no AKI, electrolytes within normal limits, chest x-ray without evidence of underlying pneumonia or pneumothorax.  I have reevaluated patient, patient has been reporting a ongoing headache for which she has a history of and takes Fioricet, requesting Fioricet.  Will order Fioricet.  We attempted to take patient off of her oxygen however when taken off the oxygen she drops to 88% on room air.  Patient reports ongoing generalized weakness and nausea which has required an additional 4 mg Zofran.  Given that patient has been monitored for couple of hours and has had ongoing nausea and vomiting, generalized weakness in the setting of hypoxia when taken off of oxygen will obtain troponins and admit patient to the hospital for obs.  I have spoken to Dr. who has accepted patient to observation with telemetry for further management.  Patient was informed of admission status, with no further questions at this time.
Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021); Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021); No adverse event; Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021); This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021)), INTERCHANGE OF VACCINE PRODUCTS (Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021)), COVID-19 IMMUNISATION (Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021)) and NO ADVERSE EVENT (No adverse event) in a 70-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: PFIZER BIONTECH COVID-19 VACCINE on 05-May-2021. Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE.    On 02-Dec-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Dec-2021, the patient experienced WRONG PRODUCT ADMINISTERED (Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021)). On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021)), COVID-19 IMMUNISATION (Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021)) and NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021)), INTERCHANGE OF VACCINE PRODUCTS (Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021)), COVID-19 IMMUNISATION (Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021)) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for WRONG PRODUCT ADMINISTERED (Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021)), INTERCHANGE OF VACCINE PRODUCTS (Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021)) and COVID-19 IMMUNISATION (Patient had 1st dose of Pfizer (05May2021), 2nd dose was Moderna Covid-19 booster (monovalent) (02Dec2021)).    No concomitant medications were provided. No treatment medication was provided.
The bottom of his feet starting burning.  No redness or difference to touch, he just felt it.
Sore arm; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP), Program ID.  A female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: MIRALAX. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "Sore arm".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300080184 Same patient/event, different vaccine dose;US-PFIZER INC-PV202300080185 Same patient, product, and event; different dose;
H1N1 vaccine at 11:45, to nurses' clinic with c/o abd. pain and temp 103.2 at 13:35. No skin manifestations, lungs clear to auscultation. P 104 regular, BP 90/50,  R 28, T 102.8 at 12:50pm. Temp 101.8 at 1:25pm TYLENOL 10cc at 1:28pm.
Upon receiving the vaccination, I was feeling faint.  Arrived at home, within two hours, hives developed over my entire body and a rash on my face and neck which was red and burning.   My breathing was compromised and I was wheezing.  My scalp was itching.   I became nauseous and vomited several times.  Heart was palpitating.
This spontaneous report as received from a 59 year old male patient who recovered from an unspecified cancer in July 2012 and with no drug reactions/allergies. The consumer stated that he received ZOSTAVAX (0.65 ml/ 1 shot, injection, lot#, route were unspecified) in approximately October 2009, "about three and a half months ago". Concomitant therapies included atenolol, CRESTOR and fenofibrate. A couple of days later (unspecified in 2009), patient broke out with sores all over his arms, buttocks, head, and back and also developed a couple of unspecified lumps on his back. He was prescribed an unspecified medication administered as two weekly treatments of "6 pills" taken simultaneously a week apart on the same day of the week. He stated that these pills did eliminate the lumps but did not eliminate the sores. The consumer also stated that, as a result of his adverse experience, he saw dermatologists and had a diagnostic biopsy test to see if his reaction could have been caused by mite bites. The test for mites came back negative. The consumer also stated that he received a flu vaccine (unspecified dose and unspecified manufacturer) around the same time as receiving the ZOSTAVAX but not on the same day. The consumer also reported that he was prescribed triamcinolone acetonide cream USP 1% to treat his rash. The outcome was reported as recovering. Drug relationship was not provided. Additional information has been requested.
Information has been received from a licensed practical nurse (LPN), for the Pregnancy Registry for GARDASIL vaccine (yeast), concerning a 15 year old female with no drug allergies and no previous pregnancies who on 25-JUL-2007 was the first dose of vaccinated with GARDASIL vaccine (yeast) (lot # 658490/0802U) and on 27-OCT-2007 was the second dose of vaccinated with GARDASIL vaccine (yeast) (lot # 658282/1263U). At week 37 of pregnancy, the patient developed slight hypertension. The patient delivered a healthy baby on 28-JUN-2008. At the time of this report, the outcome of slight hypertension was unknown. The patient was seen in office. No product quality complaint was involved. Additional information has been requested. Follow-up information was received on 27-OCT-2008 from a physician who reported that the patient with a history of gastritis and her estimated conception date was 20-OCT-2007 and LMP was 06-OCT-2007 who on 28-JUN-2008 (weeks form LMP 38), delivered a normal female baby. Weight 7lbs4oz and Apgar score 8/8.  On 30-JAN-2008 serum alpha-fetaprotein test negative and on 18-APR-2008 ultrasound was normal. There was no congenital anomaly. Labor was induced at 38 weeks secondary to pre-eclampsia, 3+ protein in urine, underwent C-section after vaginal bleeding occurred during labor. The patient was also noted to ahve questionable partial placental abruption. Pre-eclampsia in mother during pregnancy with patient. Outcome was satisfactory. Upon internal reveiw, vaginal bleeding during labor which required a C section was determined to be an other important medical event. Additional information has been requested.
This spontaneous report has been received from a pharmacist concerning a patient of unknown age and gender. The patient's medical history, drug allergies, concurrent conditions and concomitant therapies were not reported. The reporter stated that on 09-OCT-2017 the patient was inadvertently vaccinated with VARIVAX 0.5 ml, with lot number M027886 and expiration date on 03-JUN-2018 (dose number and anatomical location were not provided), administered subcutaneously for prophylaxis instead of the prescribed ZOSTAVAX. It was reported that VARIVAX was reconstituted with the sterile diluent (MERCK). No adverse effects were reported.
INJECTION SITE BECAME RED, SWOLLEN, AND ITCHING Narrative:  Other Relevant History:
This spontaneous report as received from a nurse refers to unspecified patients of unknown age and gender. The patient's concurrent conditions and medical history were not reported. On 01-JUL-2015, the patients were vaccinated with improperly stored doses of PROQUAD (Merck) stock: lot number L007228 and expiration date 03-AUG-2016 (9 administered), lot number L004005 and expiration date 05-AUG-2016 (6 administered), lot number L009209 and expiration date 17-SEP-2016 (5 administered) and stock: lot number K020751 and expiration date 30-APR-2016 (2 administered) (dose and route of administration not reported). Concomitant therapy was not reported. No adverse experiences had been reported. This is one of the two reports received from the same reporter. Additional information has been requested.
On the first 15min I had hot flashes, modern headaches.  On the 12/23/2020 I had itchy eyes itchy nose but no fever it will last about 45min every  time then it went away 48hrs after.  Telehealth appointment with her employer,
Patient stated nine days after her first dose, she developed a rash on her vaccinated arm. She said her arm became sore, swollen, red, and there was "like one big hive" on the vaccinated arm. It lasted three days and only starting itching a little on day three before it disappeared.
My arm was so painful, I could not use it. It hung useless at my side. I had to move it with my other hand. By 19:00 PM, I had a low fever and went to bed. Friday morning it was back to near normal.
I24.8 DEMAND ISCHEMIA 6/2/2022 I26.99 PULMONARY EMBOLISM, UNSPECIFIED. 2/9/2022 J96.00 ACUTE RESPIRATORY FAILURE 5/13/2022 J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 6/2/2022 J96.02 ACUTE HYPERCAPNIC RESPIRATORY FAILURE 5/18/2022 J96.12 CHRONIC HYPERCAPNIC RESPIRATORY FAILURE 5/17/2022 J96.90 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 6/2/2022 I24.8 DEMAND ISCHEMIA 6/2/2022 I26.99 PULMONARY EMBOLISM, UNSPECIFIED. 2/9/2022 J96.00 ACUTE RESPIRATORY FAILURE 5/13/2022 J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 6/2/2022 J96.02 ACUTE HYPERCAPNIC RESPIRATORY FAILURE 5/18/2022 J96.12 CHRONIC HYPERCAPNIC RESPIRATORY FAILURE 5/17/2022 J96.90 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 6/2/2022 I24.8 DEMAND ISCHEMIA 6/2/2022 I26.99 PULMONARY EMBOLISM, UNSPECIFIED. 2/9/2022 J96.00 ACUTE RESPIRATORY FAILURE 5/13/2022 J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 6/2/2022 J96.02 ACUTE HYPERCAPNIC RESPIRATORY FAILURE 5/18/2022 J96.12 CHRONIC HYPERCAPNIC RESPIRATORY FAILURE 5/17/2022 J96.90 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 6/2/2022 I24.8 DEMAND ISCHEMIA 6/2/2022 I26.99 PULMONARY EMBOLISM, UNSPECIFIED. 2/9/2022 J96.00 ACUTE RESPIRATORY FAILURE 5/13/2022 J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 6/2/2022 J96.02 ACUTE HYPERCAPNIC RESPIRATORY FAILURE 5/18/2022 J96.12 CHRONIC HYPERCAPNIC RESPIRATORY FAILURE 5/17/2022 J96.90 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 6/2/2022 I24.8 DEMAND ISCHEMIA 6/2/2022 I26.99 PULMONARY EMBOLISM, UNSPECIFIED. 2/9/2022 J96.00 ACUTE RESPIRATORY FAILURE 5/13/2022 J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 6/2/2022 J96.02 ACUTE HYPERCAPNIC RESPIRATORY FAILURE 5/18/2022 J96.12 CHRONIC HYPERCAPNIC RESPIRATORY FAILURE 5/17/2022 J96.90 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 6/2/2022 I24.8 DEMAND ISCHEMIA 6/2/2022 I26.99 PULMONARY EMBOLISM, UNSPECIFIED. 2/9/2022 J96.00 ACUTE RESPIRATORY FAILURE 5/13/2022 J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 6/2/2022 J96.02 ACUTE HYPERCAPNIC RESPIRATORY FAILURE 5/18/2022 J96.12 CHRONIC HYPERCAPNIC RESPIRATORY FAILURE 5/17/2022 J96.90 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 6/2/2022
Experienced severely high fever for 15 hours. The worst was the last 3 hours: my fever was between 104-105 and would not come down even when treated with Advi and was worried that I needed to go to emergency room. Also had pain in legs, wrists, ankles
15 min after vaccine administration I was extremely dizzy/nearly fainted this lasted for 25 minutes. 2 days later I developed some redness at the sight of injection/itchiness. This got better. On day 7 after getting the vaccine I developed a firm, raised, HOT and extremely itchy area at the site of injection. This is measuring at 5cm by 5 cm on my Left deltoid.  This continues to get larger and larger.  I have also had daily headaches since the vaccine was given. I seen a doctor who recommended calling the CDC who then advised me to complete a VAERS report.
Sore arm directly after and all day.  In evening, heart suddenly started pounding and beating at 85 when typical resting pulse is 60.  Can and does happen from time to time for a couple heart beats.  Has all my life.  This time did not stop for 20 or more minutes.  I took an extra propranolol and it went back to normal in a few minutes.  Not positive it was result of injection but thought I should mention.
I had a potential covid exposure on 01/01/2022. A friend I saw that day tested positive for covid on 01/04/2022. I started feeling symptoms during the day on 01/07/2022. I was very fatigued and had a headache. I visited Medical Center on 01/08/2022. I was evaluated and given a rapid covid test which was negative. I was also given a covid PCR test. I got the results of that test on 01/09/2022. It was negative. I am still experiencing some fatigue and headaches. I have been working from  home this week.
Blood clots; strokes; This is a spontaneous report from a contactable consumer. A 81-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot Number: FT8886), via an unspecified route of administration, administered in left arm on an unknown date in Feb2021 (at the age of 81-year-old) as dose 2, single dose for COVID-19 immunisation. Medical history included type II diabetes, arthritis and fibromyalgia. Prior to the vaccination, the patient was not diagnosed with COVID. The patient taken other medications in two weeks: insulin shots, prescription pain medications, urine medications and anxiety medications. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot Number: not reported), administered in left arm on an unknown date in Feb2021 (at the age of 81-year-old) as dose 1, single for COVID-19 immunisation. The patient did not receive other vaccine in four weeks. Post vaccination, the patient had not been tested for COVID. On an unknown date in Apr2021, the patient had blood clots and strokes. The events resulted in emergency room/department or urgent care, hospitalized for 7 days. The patient did not receive any treatment in response to the events. The patient died on 31May2021. An autopsy was not performed. Cause of death was reported as blood clots and strokes. Outcome of the events was fatal.  Information about lot/batch number has been requested.; Reported Cause(s) of Death: Blood clots; strokes
Rash developed on trunk and extremities and a bump developed at the  left thigh injection site.
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose01/07/21 2nd dose01/28/21 Diagnosed covid positive:09/01/21 Symptom onset:08/31/21 Exposure: Symptoms:fatigue,sore throat.
606 doses were given after expiration date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (606 doses were given after expiration date) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were provided  Date place in refrigerator 18-Oct-2021. No adverse events were reported. No temperature excursion of the product was reported.  No treatment details were provided
Patient received VARIVAX on 9/26/02 in the right thigh.  She returns to clinic on 9/22/03 with a diagnosis of shingles.  It is described in the medical record as "cluster of shallow lesions without drainage in an area from right lateral lower abdomen down to public area.  Single lesion on upper right buttocks."
Shingles; Pain; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 72-year-old female patient who received Herpes zoster (Shingrix) (batch number EZ4TD, expiry date 4th November 2022) for prophylaxis.   On 22nd January 2021, the patient received the 1st dose of Shingrix. On an unknown date, less than 2 months after receiving Shingrix, the patient experienced shingles and pain. On an unknown date, the outcome of the shingles was recovered/resolved and the outcome of the pain was recovering/resolving.   It was unknown if the reporter considered the shingles and pain to be related to Shingrix.  Additional details were provided as follows: The patient experienced an active case of Shingles after receiving Shingrix.  The patient had a pain for 3 days, but she was better and there were no active shingles at the time of reporting.  The reporter inquired if they could give the 2nd dose to the patient. The consent to follow up was provided.  The batch number of Shingrix was reported as E24TD, which was corrected to EZ4TD as per sales data sheet.
Swelling and Redness, warmth in area of shot. The areas was approximately an 1 and half inches in diameter. She also experienced rash that developed on Sat on both the right leg and left. Patient did take a BENADRYL.
really sick; chest pains; will not take the second shot; pretty bad cold; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (really sick) and CHEST PAIN (chest pains) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Asthma.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, the patient experienced NASOPHARYNGITIS (pretty bad cold). On an unknown date, the patient experienced MALAISE (really sick) (seriousness criterion hospitalization), CHEST PAIN (chest pains) (seriousness criterion hospitalization) and TREATMENT NONCOMPLIANCE (will not take the second shot). At the time of the report, MALAISE (really sick), CHEST PAIN (chest pains), TREATMENT NONCOMPLIANCE (will not take the second shot) and NASOPHARYNGITIS (pretty bad cold) outcome was unknown. Not provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient's weight is 170 (units not reported). Whilst hospitalized, all laboratory tests (unspecified) were normal. Concomitant medication included unspecified medication for asthma.  Treatment information was not provided.  Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
*Per mom on 06/19/14, all (3) vaccine sites with redness and a little raised on (LT) thigh, took about 1 wk to resolve; (RT) thigh at 2 sites), resolved in about 1-2 days, all without tx. Denies fever or hives.
Pt vaccinated 3 doses Recombivax appox 1988; PE lab eval revealed GGTP over 200; pt liver func w/an ultrasound & CT scan has yielded no other abn;
Palpitations at rest( HR 132), headache , swollen lymph nodes in Left arm  pit. EKG -sinus tachycardia with right axis deviation
Two hours after waking up today (and 17 hours after shot), I started getting the same symptoms as when I actually had the Coronavirus during the end of June/beginning of July:  fluctuating chills/sweats, enflamed throat, achey muscles,  fatigue and a temperature of 100.1 at last check.  Took a 2 hour nap but it did not help.  I do not think it is a hospital trip by any means. advice?